

Press release

Medios expects further growth in revenue and earnings after record year 2024

- Consolidated revenue increases to €1.9 billion (+5.5%)
- EBITDA pre¹ with disproportionate growth of 30.5% and significantly improved EBITDA pre¹ margin of 4.2% (previous year: 3.4%)
- Strong operating cash flow
- Outlook for 2025: revenue growth to around €2.0 billion; EBITDA pre¹ growth to around €96 million with significantly higher EBITDA pre¹ margin of around 4.8%

Berlin, March 25, 2025 – The Medios Group ("Medios"), a leading provider of Specialty Pharma in Europe, has once again achieved record results in the 2024 financial year. Consolidated revenue increased by 5.5% year on year to €1.9 billion (previous year: €1.8 billion). EBITDA pre¹ rose significantly by 30.5% to €79 million (previous year: €60.5 million). The EBITDA pre¹ margin improved significantly to 4.2% (previous year: 3.4%). The disproportionate increase in EBITDA pre¹ is due in particular to the acquisition of the Ceban Group and the associated internationalization.

In addition, the operating cash flow reached an exceptionally high level of €73.7 million, reflecting the positive development of the operating result and a reduction in net working capital as of the reporting date. The audited results for 2024 are thus in line with the adjusted forecast of December 12, 2024 and confirm the preliminary figures published on March 4, 2025.

Matthias Gaertner, CEO of Medios AG: "We have significantly and sustainably increased our profitability in 2024. At the same time, we have consistently driven forward the development of our European Specialty Pharma platform and further expanded our business in the field of Advanced Therapies. The exceptionally high operating cash flow is proof of our company's financial strength. We will continue on this positive development in 2025 and push ahead with our profitable growth. We expect to see a further significant increase in the EBITDA pre¹ margin to around 4.8%."

All operating segments contributed to increase in earnings

In the **Pharmaceutical Supply** segment, external revenue rose to €1,580.0 million in the 2024 financial year (previous year: €1,558.1 million), which corresponds to a slight growth of 1.4% compared to the previous year. EBITDA pre¹ increased disproportionately by 7.2% to €50.0 million (previous year: €46.7 million).

The **Patient-Specific Therapies** segment generated external revenue of €213.6 million (previous year: €226.0 million), a slight decline of 5.5%. By contrast, EBITDA

pre¹ increased by 6.6% to €23.3 million (previous year: €21.8 million), thanks in particular to strong growth in the second half of 2024.

The increases in earnings in the segments of Pharmaceutical Supply and Patient-Specific Therapies were achieved exclusively organically.

The **International Business** segment comprises the activities of Ceban Pharmaceuticals B.V. (“Ceban”), which has been included in the scope of consolidation since June 1, 2024. The segment contributed significantly to the positive development of the Medios Group in the 2024 financial year, with external revenue of €88.8 million and EBITDA pre¹ of €16.3 million.

Positive outlook for the 2025 financial year

For the 2025 financial year, the Medios Group expects an increase in revenue of around 6% to around €2 billion. EBITDA pre¹ is expected to increase disproportionately by around 21.5% to around €96 million. This corresponds to a further increase in the EBITDA pre¹ margin to around 4.8%. This expectation is based on the assumption of organic growth in the mid-single-digit percentage range and takes into account the consolidation of the Ceban Group for twelve months.

Key figures (IFRS)

in € million

	2024	2023	Δ in %
Revenue	1,883.0	1,784.7	5.5
Pharmaceutical Supply	1,580.0	1,558.1	1.4
Patient-Specific Therapies	213.6	226.0	-5.5
International Business	88.8	n/a	n/a
Services	0.6	0.6	4.9
EBITDA pre¹	79.0	60.5	30.5
Pharmaceutical Supply	50.0	46.7	7.2
Patient-Specific Therapies	23.3	21.8	6.6
International Business	16.3	n/a	n/a
Services	-10.5	-8.0	30.9
Cash flow from operating activities	73.7	16.4	>100

The 2024 Annual Report is available for [download](#) on the Investor Relations website.

Important dates for Medios Group in the 2025 financial year:

April 03	Metzler Small Cap Days Conference – Frankfurt
May 13	Quarterly Statement as of March 31, 2025
May 27	Ordinary Annual General Meeting 2025 (AGM)
August 13	Half-Year Financial Report
September 24	Berenberg Fourteenth German Corporate Conference – Munich
November 11	Quarterly Statement as of September 30, 2025

¹ EBITDA is defined as consolidated earnings before interest, taxes, depreciation and amortization. EBITDA pre is adjusted for special charges for stock options, expenses for M&A activities and for 2023 and 2024 for performance-based payments for the acquisition of compounding volumes as well as from 2024 expenses for ERP-System implementation.

About Medios AG

Medios is a leading provider of Specialty Pharma in Europe. With locations in Germany, the Netherlands, Belgium and Spain, the company supports key partners in the supply chain with innovative solutions and intelligent services. Medios has focused on pioneering individualized medicine to make the most innovative therapies available to everyone together with pharmacies, specialist practices and pharmaceutical companies.

Medios AG is Germany's first listed specialty pharmaceutical company. The shares are listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) and are included in the SDAX selection index.

www.medios.group

Contact

Claudia Nickolaus
Head of Investor & Public Relations, ESG Communications
Medios AG
Heidestraße 9 | 10557 Berlin
T +49 30 232 566 800



ir@medios.group
www.medios.group

Disclaimer

This communication contains forward-looking statements that are subject to certain risks and uncertainties. Future results could differ materially from those currently anticipated as a result of various risk factors and uncertainties, including, but not limited to, changes in business, economic and competitive conditions, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. Medios AG assumes no responsibility to update any forward-looking statements contained in this release.

—

—

—
—